• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

    2/7/24 12:01:48 PM ET
    $XBIT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XBIT alert in real time by email
    SC 13G/A 1 sc13ga_020724.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    XBIOTECH INC.
    (Name of Issuer)
     
    Common Shares, no par value
    (Title of Class of Securities)
     
    98400H102
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [_] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [x] Rule 13d-1(d)

     

    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 98400H102

     

     

    1  

    Names of Reporting Persons

     

     

    Thomas Gut

     

     
    2   Check the appropriate box if a member of a Group (see instructions)
         
      (a)  [ ]  
      (b)  [ ]  
    3   Sec Use Only  
     

     

     

     
    4   Citizenship or Place of Organization
     

     

    Switzerland

     

     
    Number of Shares Beneficially Owned by Each Reporting Person With: 5   Sole Voting Power
     

     

    3,914,111

     

    6   Shared Voting Power
     

     

     

    7   Sole Dispositive Power
     

     

    3,914,111

     

    8   Shared Dispositive Power
     

     

     

    9   Aggregate Amount Beneficially Owned by Each Reporting Person
     

     

    3,914,111

     

     
    10   Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
     

     

    [ ]

     

     
    11   Percent of class represented by amount in row (9)
     

     

    12.86%

     

     
    12   Type of Reporting Person (See Instructions)
     

     

    IN

     

     

     

     

     

     

    Item 1.

     

      (a) Name of Issuer:

     

    XBiotech Inc.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    5217 Winnebago Ln, Austin, TX 78744

     

    Item 2.

     

      (a) Name of Person Filing:

     

    Thomas Gut 

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    Thomas Gut

    c/o Lindenberg Family Office Ltd.

    Laternengasse 5

    8001 Zurich, Switzerland

     

      (c) Citizenship:

     

    Switzerland

     

      (d) Title and Class of Securities:

     

    Common Shares, no par value

     

      (e) CUSIP No.:

     

    98400H102

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)   ◻   Broker or dealer registered under Section 15 of the Act;
               
      (b)   ◻   Bank as defined in Section 3(a)(6) of the Act;
               
      (c)   ◻   Insurance company as defined in Section 3(a)(19) of the Act;
               
      (d)   ◻   Investment company registered under Section 8 of the Investment Company Act of 1940;
               
      (e)   ◻   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
               
      (f)   ◻   An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
               
      (g)   ◻   A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
               
      (h)   ◻   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
               
        (i) ◻   A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;
               
        (j) ◻   Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
                   

     

    Not Applicable

     

    Item 4. Ownership

     

    As of December 31, 2023

     

      (a) Amount Beneficially Owned:

     

    3,914,111 shares

     

      (b) Percent of Class:

     

    12.86% Based upon 30,436,964 shares outstanding as of December 31, 2023.

     

      (c) Number of shares as to which such person has:

     

     

        (i)  Sole power to vote or to direct the vote:

     

    3,914,111 shares

     

     

     

     

       

    (ii)

    Shared power to vote or to direct the vote:

     

     

        (iii)  Sole power to dispose or to direct the disposition of:

     

    3,914,111 shares

     

        (iv)  Shared power to dispose or to direct the disposition of:

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not Applicable

     

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.
       
      Not Applicable

     

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
       
      Not Applicable

     

    Item 8. Identification and classification of members of the group.
       
      Not Applicable

     

    Item 9. Notice of Dissolution of Group.
       
      Not Applicable

     

    Item 10. Certifications.
       
      Not Applicable

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 7, 2024

     

    /s/ Thomas Gut

     

    Thomas Gut

     

     

     

     

     

    Get the next $XBIT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XBIT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XBIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XBiotech Pauses Rheumatology program

      AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid Arthritis. The Phase II study failed to meet its primary endpoint amid substantial irregularities that make unequivocal interpretation of the findings difficult. XBiotech was planning launch of additional studies in arthritis as well as other areas of rheumatology, including ankylosing spondylitis, which are now on hold while recent findings are evaluated. About 230 subjects with modera

      12/23/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

      AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might po

      6/18/24 11:35:14 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

      AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate we

      1/4/24 9:00:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by XBiotech Inc.

      10-K/A - XBiotech Inc. (0001626878) (Filer)

      4/29/25 3:59:49 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - XBiotech Inc. (0001626878) (Filer)

      4/7/25 4:50:51 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Inc. filed SEC Form 8-K: Leadership Update

      8-K - XBiotech Inc. (0001626878) (Filer)

      3/31/25 6:43:56 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      3/19/25 3:03:42 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Simard John

      4 - XBiotech Inc. (0001626878) (Issuer)

      2/4/25 4:53:27 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mckenzie W Thorpe

      4 - XBiotech Inc. (0001626878) (Issuer)

      6/21/24 2:16:44 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:36:43 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:48 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XBiotech Inc. (Amendment)

      SC 13G/A - XBiotech Inc. (0001626878) (Subject)

      2/7/24 12:01:06 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XBIT
    Financials

    Live finance-specific insights

    See more
    • XBiotech Announces Payment of Dividend to Holders of Common Stock

      AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech's balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug

      7/30/21 11:03:00 AM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XBiotech Announces Dividend to Holders of Common Stock

      AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. "XBiotech's proven ability to develop highly valued drug candidates, revenue from contract operations, judicious deployment of operating capital, absence of debt, and very significant emerging opportunities in our pipeline, has created the balance sheet flexibility that enables us to provide shareholder

      7/6/21 4:30:00 PM ET
      $XBIT
      Biotechnology: Pharmaceutical Preparations
      Health Care